The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Retaane     [2-[(8S,10R,13S,14S,17R)-17- hydroxy-10,13...

Synonyms: Anecortave, SureCN94110, AG-K-31568, CHEMBL2106613, NSC-15475, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D01733


High impact information on D01733


Chemical compound and disease context of D01733


Biological context of D01733


Anatomical context of D01733

  • Studies show that posterior juxtascleral depot administration of anecortave acetate is an effective, minimally invasive method of delivering this drug to the choroid and retina [7].
  • Two of the most potent angiostatic steroids, AL-3789 and AL-4940, were evaluated for glucocorticoid-mediated antiinflammatory activity in the in vitro U937 cell model of LPS-induced IL-1 induction and found to be devoid of glucocorticoid activity [10].

Associations of D01733 with other chemical compounds


Gene context of D01733


Analytical, diagnostic and therapeutic context of D01733

  • On days 21 and 28 the net tumor weight of the AL-3789-treated animals was 40% to 30% of controls (P < 0.05) [5].
  • Three doses of AL-3789 (0.01%, 0.1%, and 1%) were also evaluated in a prevention treatment protocol [2].
  • The Anecortave Acetate and photodynamic therapy (PDT) with verteporfin Combination Trial enrolled 136 patients randomized to PDT with verteporfin followed by a single depot administration of anecortave acetate (15 mg or 30 mg) or vehicle [16].
  • Results of initial studies led to the design of a new cannula that could effectively deliver anecortave acetate as a posterior juxtascleral depot, providing adequate retinal and choroidal drug concentrations for up to 6 months after a single administration [7].
  • METHODS: Detailed ophthalmic examinations, physical examinations, and adverse event reporting were used to characterize the clinical safety of anecortave acetate 15 mg and were monitored by an Independent Safety Committee. RESULTS: Anecortave acetate 15 mg was safe and well tolerated in the overall patient population [6].


  1. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Jockovich, M.E., Murray, T.G., Escalona-Benz, E., Hernandez, E., Feuer, W. Invest. Ophthalmol. Vis. Sci. (2006) [Pubmed]
  2. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. BenEzra, D., Griffin, B.W., Maftzir, G., Sharif, N.A., Clark, A.F. Invest. Ophthalmol. Vis. Sci. (1997) [Pubmed]
  3. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Penn, J.S., Rajaratnam, V.S., Collier, R.J., Clark, A.F. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  4. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. D'Amico, D.J., Goldberg, M.F., Hudson, H., Jerdan, J.A., Krueger, D.S., Luna, S.P., Robertson, S.M., Russell, S., Singerman, L., Slakter, J.S., Yannuzzi, L., Zilliox, P. Ophthalmology (2003) [Pubmed]
  5. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Clark, A.F., Mellon, J., Li, X.Y., Ma, D., Leher, H., Apte, R., Alizadeh, H., Hegde, S., McLenaghan, A., Mayhew, E., D'Orazio, T.J., Niederkorn, J.Y. Invest. Ophthalmol. Vis. Sci. (1999) [Pubmed]
  6. Clinical Safety Profile of Posterior Juxtascleral Depot Administration of Anecortave Acetate 15 mg Suspension as Primary Therapy or Adjunctive Therapy with Photodynamic Therapy for Treatment of Wet Age-Related Macular Degeneration. Regillo, C.D., D'Amico, D.J., Mieler, W.F., Schneebaum, C., Beasley, C.H., Sullins, G.T. Survey of ophthalmology (2007) [Pubmed]
  7. Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Dahlin, D.C., Rahimy, M.H. Survey of ophthalmology (2007) [Pubmed]
  8. ANECORTAVE ACETATE TREATMENT FOR RETINAL ANGIOMATOUS PROLIFERATION: A Pilot Study. Klais, C.M., Eandi, C.M., Ober, M.D., Sorenson, J.A., Sadeghi, S.N., Freund, K.B., Spaide, R.F., Slakter, J.S., Yannuzzi, L.A. Retina (Philadelphia, Pa.) (2006) [Pubmed]
  9. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. D'Amico, D.J., Goldberg, M.F., Hudson, H., Jerdan, J.A., Krueger, S., Luna, S., Robertson, S.M., Russell, S., Singerman, L., Slakter, J.S., Sullivan, E.K., Yannuzzi, L., Zilliox, P. Retina (Philadelphia, Pa.) (2003) [Pubmed]
  10. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. McNatt, L.G., Weimer, L., Yanni, J., Clark, A.F. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (1999) [Pubmed]
  11. The Digital Angiography Reading Center (DARC) Role in the Anecortave Acetate Clinical Trials. Slakter, J.S., Carvalho, C., Coleman, H. Survey of ophthalmology (2007) [Pubmed]
  12. Evolving European guidance on the medical management of neovascular age related macular degeneration. Chakravarthy, U., Soubrane, G., Bandello, F., Chong, V., Creuzot-Garcher, C., Dimitrakos, S.A., Korobelnik, J.F., Larsen, M., Monés, J., Pauleikhoff, D., Pournaras, C.J., Staurenghi, G., Virgili, G., Wolf, S. The British journal of ophthalmology. (2006) [Pubmed]
  13. Progressive Visual Loss in Subfoveal Exudation in Age-related Macular Degeneration: A Meta-analysis Using Lineweaver-Burke Plots. Shah, A.R., Del Priore, L.V. Am. J. Ophthalmol. (2007) [Pubmed]
  14. Suppression of Laser-Induced Choroidal Neovascularization by Subconjunctival Injection of 9alpha-Fluoromedroxyprogesterone Acetate (FMPA), an Anti-angiogenic Agent, in Rats. Murata, N., Yamaji, T., Uchida, M., Tsuboi, H., Suzuki, H., Yamada, M., Oikawa, T., Nobuhiro, J., Choshi, T., Hibino, S. Biol. Pharm. Bull. (2006) [Pubmed]
  15. ANECORTAVE ACETATE FOR THE TREATMENT OF IDIOPATHIC PERIFOVEAL TELANGIECTASIA: A Pilot Study. Eandi, C.M., Ober, M.D., Freund, K.B., Klais, C.M., Slakter, J.S., Sorenson, J.A., Yannuzzi, L.A. Retina (Philadelphia, Pa.) (2006) [Pubmed]
  16. Anecortave acetate for the treatment of exudative age-related macular degeneration-a review of clinical outcomes. Russell, S.R., Hudson, H.L., Jerdan, J.A. Survey of ophthalmology (2007) [Pubmed]
WikiGenes - Universities